Skip to main content

Table 1 FDA-approved targeting nanodrugs for HER2-positive breast cancer

From: Nanotechnology approaches to addressing HER2-positive breast cancer

Targeting drug specific to HER2 Mechanism of action Reference
Trastuzumab (Herceptin) Monoclonal antibody that binds to the extracellular domain (ECD) of the HER2/neu receptor Targeted therapy (2019)
Pertuzumab (Perjeta) Inhibits dimerization of HER2 receptors by binding to special epitope of the extracellular domain (ECD) PERJETA and HER2+ breast cancer (2019)
Ado-trastuzumab emtansine (Kadcyla or TDM-1) Targets HER2 receptors with trastuzumab and delivers the inhibitor emtancine to arrest and kill cancer cells (2019)
Lapatinib Receptor tyrosine kinase inhibitor in the ICD Targeted therapy (2019)
Neritinib Receptor tyrosine kinase inhibitor in the ICD U.S. National Library of Medicine (2019)
Bevacizumab VEGF inhibitor; reduces the cancers blood supply Targeted therapy, 2019
Fam-trastuzumab-deruxtecan Humanized IgG1 monoclonal antibody, which has the same amino acid sequence as trastuzumab (and targets HER2. The deruxtecan component is a topoisomerase inhibitor Fam-Trastuzumab Deruxtecan (2020)
Tucatinib Selectively binds to and inhibits the phosphorylation of ErbB-2, which may prevent the activation of ErbB-2 signal transduction pathways, resulting in growth inhibition and death of ErbB-2-expressing tumor cells Tucatinib (2020)